The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma
- 6 September 2019
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 44 (2) , 149-161
Abstract
The frequency and prognostic significance of the histologic type in early-stage ovarian cancer (OC) is not as well established as in advanced stages. In addition, histologic typing based only on morphologic features may be difficult, especially in high-grade tumors. In this study, we have analyzed a prospective cohort of 502 early-stage OCs to investigate their frequency, immunohistochemical characteristics, and survival of the 5 main histologic types. Histotype was assigned according to not only the morphologic features but also according to the expression pattern of WT1, p53, Napsin A, and progesterone receptors. In addition, an extended panel including p16, β-catenin, HER2, Arid1A, HINF1B, CK7, CDX2, and CK20 was used to refine the diagnosis in difficult cases. In this series, the frequency of the 5 major histologic types was as follows: endometrioid carcinoma, 32.7%; clear cell carcinoma, 25.1%; high-grade serous carcinoma (HGSC), 24.7%; mucinous carcinoma, 10.2%; low-grade serous carcinoma, 4.6%; and others, 2.8%. The combination of morphology and immunohistochemistry allowed the reclassification of 23% of OCs. The lowest concordance was found between samples initially diagnosed as endometrioid, but finally classified as high-grade serous tumors (22% error rate). Endometrioid carcinoma was the most favorable histologic type, whereas HGSC and low-grade serous carcinoma had the worst prognosis. Clear cell carcinoma with abnormal p53 immunostaining pattern also had poor prognosis. Although histologic grade was not a prognostic factor among early-stage endometrioid OCs, distinction between grade 3 endometrioid OC and HGSC is recommended, taking into account differences in prognosis and molecular alterations that can guide different treatments.Keywords
This publication has 41 references indexed in Scilit:
- HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian CancerPLOS ONE, 2013
- Clinicopathologic Analysis of Low-stage Sporadic Ovarian CarcinomasAmerican Journal of Surgical Pathology, 2013
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012
- Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell CarcinomaInternational Journal of Molecular Sciences, 2010
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Diagnosis of Ovarian Carcinoma Cell Type is Highly ReproducibleAmerican Journal of Surgical Pathology, 2010
- Differences in Tumor Type in Low-stage Versus High-stage Ovarian CarcinomasInternational Journal of Gynecological Pathology, 2010
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998